What Progeffik Treats: Main Uses and Benefits

The therapeutic uses of Progeffik, which contains micronized progesterone, are relevant across areas of female health and may assist with managing symptomatic conditions related to hormone deficiency. The active substance in this medication is utilized for supportive management within these clinical areas.

It is applied in addressing conditions related to functional progesterone deficiency, notably the significant irregularity or absence of menstruation (amenorrhea), and contributes to easing the risk of endometrial hyperplasia when used as part of Hormone Replacement Therapy (HRT). Furthermore, this medication is relevant for situations involving certain distressing symptoms in reproductive medicine, including luteal phase insufficiency and supportive management during Assisted Reproductive Technology (ART) cycles like IVF.

---

Quick Fact: Support for Systemic Imbalance

This therapy may assist with achieving hormonal equilibrium, which supports the regulation of the menstrual cycle and contributes to improved comfort during periods of menopausal symptoms. The use of progestogens is applied in addressing a wide range of gynecological and obstetric conditions.

Regulatory References

1. NIH StatPearls overview

Eligibility and Contraindications

The use of Progeffik (micronized progesterone) is strictly governed by official regulatory standards that define who is eligible and who is prohibited from using the medicine.

Absolute Contraindications (Prohibited Use)

Use is strictly prohibited for patients with certain severe pre-existing conditions, including severe hepatic dysfunction, known or suspected hormone-dependent malignancies (such as breast cancer), and active or past venous or arterial thromboembolic disorders. The medicine is also contraindicated in patients with known thrombophilic disorders, undiagnosed vaginal bleeding, and known hypersensitivity to the active ingredient or excipients (e.g., soya or peanut).

Age and Conditional Restrictions

Eligibility is primarily limited to adult women; use is officially not established or not recommended for pediatric and adolescent populations. For pregnancy, use is conditional and permitted only for specific regulatory indications, such as luteal phase support or the prevention of preterm birth. Use is officially not recommended or contraindicated while breastfeeding. Patients with mild to moderate hepatic impairment, renal disease, hypertension, or diabetes mellitus require close medical supervision and conditional use.

Interactions with other medicines and products

Official regulatory information highlights several areas where Progeffik (micronized progesterone) may interact with other medicinal products and substances. These interactions primarily affect the plasma concentration of progesterone or the effectiveness of co-administered treatments.

Documented Pharmacokinetic Changes

The metabolism of progesterone can be altered by certain enzyme modulators. Enzyme inhibitors, such as Ketoconazole (a potent CYP3A4 inhibitor), may increase the bioavailability and concentration of Progeffik. Conversely, enzyme inducers (e.g., Perampanel, Topiramate, and the herbal product St John's Wort) may increase progesterone's metabolism, potentially lowering its concentration and effectiveness. Similarly, some antibiotics (Ampicillin, Amoxicillin, Tetracyclines) are noted to lower the concentration of steroids in the blood.

Progeffik may also affect other drugs: it is documented to prevent the metabolism of Ciclosporin, leading to an increase in Ciclosporin's plasma concentration.

Pharmacodynamic and Other Considerations

Progestogens may affect the treatment balance of diabetes, potentially requiring adjustments to antidiabetic medication. Furthermore, Progeffik may affect the activity of certain anticoagulants, specifically altering the effect of Coumarins and Phenindione.

Finally, concomitant food ingestion increases the bioavailability of the oral capsule form of Progeffik. Caution and careful monitoring are advised in patients with renal dysfunction due to the importance of the kidneys in metabolite elimination.

Progeffik, which contains progesterone, functions primarily as an agonist for the intracellular Progesterone Receptors (PRs), specifically the isoforms PR-A and PR-B. Following cellular uptake, progesterone binds to the inactive cytoplasmic PR complex, causing a conformational change that releases the receptor from heat shock proteins. The activated receptor then undergoes dimerization and translocates into the nucleus.

In the nucleus, the PR dimer binds to specific DNA sequences known as Progesterone Response Elements (PREs) located in the promoter regions of target genes. This DNA binding modulates the transcription of downstream genes by recruiting coactivators or corepressors, resulting in altered protein synthesis. This genomic mechanism regulates key cellular processes, including cell differentiation, proliferation, and secretion, particularly within reproductive tissues. Progesterone also acts rapidly via non-genomic mechanisms by binding to membrane progesterone receptors (mPRs) and modulating intracellular signaling cascades, such as the MAPK and Akt pathways, which leads to immediate changes in cellular activity.

How Progeffik Is Used: Official Administration Guidelines

Progeffik (micronized progesterone) is administered according to specific guidelines that define the route, dosage, timing, and duration of use. These instructions are contingent on the treatment context, primarily utilizing either oral or vaginal administration routes, though availability may vary by region.

---

Official Administration Protocols

The standard adult dosing regimens and usage patterns are defined by established clinical parameters:

Context of Use	Daily Dose and Route	Frequency and Duration Pattern
Hormone Replacement Therapy (HRT)	200 mg once daily, oral.	Cyclic use: 12 consecutive days per 28-day cycle.
Secondary Amenorrhea	400 mg once daily, oral.	Intermittent use: 10 consecutive days per cycle.
Luteal Phase Support (ART)	Up to 600 mg daily, vaginal.	Duration: Continued until the 12th week of pregnancy.

---

Procedural Instructions and Constraints

Administration involves specific timing and food relationship considerations. The oral dose is typically taken at bedtime to align with the body’s hormonal cycle and is taken without food or at least two hours after a meal to manage absorption. The capsule is swallowed whole with water. When used vaginally, the capsule is inserted deep into the vagina.

Usage guidelines include specific restrictions: the oral form is generally contraindicated in cases of severe hepatic impairment, and the medication is not indicated for use in the pediatric population. Furthermore, this medication, when used under these conditions, does not function as a contraceptive. These procedural and scheduling rules standardize the delivery of the hormone throughout the required phase of treatment.

Research Evidence / Overview of Studies for Progeffik (Micronized Progesterone)

---

Evidence for Use in Endometrial Protection

Research examining endometrial protection in the context of micronized progesterone primarily relies on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies research examined patterns in the lining of the uterus, known as the endometrium, when it was observed in cohorts receiving estrogen as part of Hormone Replacement Therapy (HRT) for women who still have their uterus. Research examined outcomes related to the incidence of abnormal cell growth, known as Endometrial Hyperplasia.

Studies reported measurements of Endometrial Histology patterns when the medication was observed in cohorts receiving estrogen therapy. It is not yet clear whether the specific dose and administration schedule used in trials fully characterize the full range of observed outcomes for all women, as findings may vary based on whether the regimen is continuous or sequential. While follow-up durations are often intermediate- to long-term, long-term effects are not fully established beyond five years of observation in all study types.

---

Evidence for Use in Assisted Reproductive Technology (ART)

Research into micronized progesterone's use for Luteal Phase Support during procedures like in vitro fertilization (IVF) is largely driven by numerous Randomized Controlled Trials (RCTs) and Meta-analyses. These studies track the study intervention's duration from the time of egg retrieval until the early stages of pregnancy. Researchers examine critical clinical outcomes related to the reproductive cycle, including the Ongoing Pregnancy Rate and the Live Birth Rate.

Trials report patterns related to the monitored Ongoing Pregnancy Rates and Live Birth Rates when the medication was used in the luteal phase. Comparative studies have explored whether different ways of giving the medication (such as oral versus vaginal routes) were associated with similar clinical outcomes. A key area of uncertainty is establishing the optimal administration route for all patients, as findings were mixed in some trials comparing oral and vaginal formulations. Furthermore, comparative evidence is limited when evaluating micronized progesterone against all alternative progestogens used for this purpose.

---

Evidence in Special Populations and Research Gaps

Research exploring the use of the medication for cycle regulation includes Prospective Studies and clinical trials conducted in adult women with evidence of hormonal deficiency. These studies were used to examine outcomes related to the occurrence of withdrawal bleeding. Data for certain groups remain insufficient, particularly for outcomes in pediatric populations or older adults. Overall, the research highlights what is known—and what is still uncertain. Comparative evidence is limited for certain subgroups, and subgroup findings are uncertain when trying to generalize research from one large population (like IVF) to all conditions characterized by systemic or functional imbalance. Research is ongoing to explore different formulations, administration routes, and long-term effects across approved uses.

Key Studies & References

1. Key to Life: Physiological Role and Clinical Implications of Progesterone (Review article covering multiple indications)
2. Progestins - StatPearls - NCBI Bookshelf (Section on HRT and Amenorrhea)

Common questions about Progeffik (FAQ)

---

Q: What is the difference between oral and vaginal use of Progeffik?

The choice between oral and vaginal routes impacts how the medicine is absorbed by the body. Official product information indicates that oral administration leads to high levels of progesterone in the entire system, and its breakdown products (metabolites) can cause central nervous system effects like drowsiness. Vaginal administration results in lower amounts of the hormone circulating in the blood but provides high local concentrations in the uterus, which is the method typically used for specific treatments like luteal phase support in regulatory trials.

---

Q: How long does it take for Progeffik to start working?

When Progeffik is absorbed, the concentration of progesterone in the blood reaches its highest point at different times depending on the route. According to official pharmacokinetic data, this typically occurs about 1 to 4 hours after taking the capsule by mouth and 2 to 8 hours after it is inserted vaginally. This timeframe indicates when the drug's concentration is at its highest in the bloodstream.

---

Q: How is Progeffik eliminated from the body?

Regulatory documents explain that progesterone is processed primarily in the liver into various compounds called metabolites. These metabolites are then mainly removed from the body by the kidneys and excreted in the urine as conjugates. A smaller amount of the metabolites is also eliminated through the bile and feces.

---

Q: What should I do if I miss a dose of Progeffik?

The patient information leaflet typically advises that a missed dose may be taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, official instructions usually recommend skipping the missed dose and returning to the regular dosing schedule. Taking a double dose is generally advised against to make up for a forgotten one.

---

Q: What if I have an allergic reaction to Progeffik's capsule ingredients (like soya or peanut)?

Official regulatory documents indicate that the medicine is contraindicated (not to be used) if a person has a known sensitivity to the active ingredient or any of the excipients, such as soya or peanut oil. The product label states that signs of a severe allergic reaction, such as difficulty breathing or swelling, require immediate medical attention.

Storage and Disposal Requirements

Official regulatory guidelines strictly define how Progeffik (progesterone soft capsules) must be stored and discarded to maintain its integrity and ensure safety.

Mandatory Storage Conditions

The medicine must be stored below 30°C.

Child Safety and Handling

It is a mandatory requirement that the product be kept out of the sight and reach of children to prevent accidental exposure.

Official Disposal Rules

Unused or expired Progeffik, along with any waste material, must not be discarded in household trash or down the toilet. Disposal must be performed strictly in accordance with local pharmaceutical waste requirements.